Alexander Elias joined Centerview Partners in London in 2010 and has extensive experience advising companies on mergers and acquisitions, and other complex strategic issues primarily in the healthcare and life sciences sector.

Alex has advised on numerous industry leading transactions including advising AstraZeneca on its $39 billion acquisition of Alexion, Capvest on its recent acquisition of a majority stake in STADA Arzneimittel, Teva on its $1.5 billion partnership with Sanofi for it’s anti- TL1A candidate duvakitug, Lupin’s $220m acquisiton of VISUfarma, and Nxera’s $0.5 billion acquisition of Idorsia’s Japan commercial stage portfolio. Alex has advised on numerous biotech transactions including Araris’s up to $1.1bn sale to Taiho, a subsidiary of Otsuka, and Neuroderm’s $1.1 billion sale to Mitsubishi Tanabe. Alexander also previously advised CSL on numerous transactions including their acquisition of Novartis’ influenza vaccine business.

Alex has also advised on numerous transactions in the broader healthcare sector including advising Walgreens Boots Alliance on its $26 billion take-private by Sycamore Partners, the $8 billion take private of Mediclinic PLC by a consortium of Remgro and MSC, Galenica on its $2 billion separation through IPO of Galenica Santé to form Vifor Pharma and the sale of ProPharma Group to Odyssey Investment Partners.

Alex was formerly a healthcare private equity investor at Permira.

Alex Elias holds an M.A. in Philosophy, Politics and Economics from the University of Oxford.